You are about to leave the Clinical Value website now.


Moving towards risk-based surveillance and early detection of hepatocellular carcinoma


Quick Summary

Dr. Amit Singal and Dr. Peter Jepson review the latest developments in risk-based surveillance and the early detection of hepatocellular carcinoma during the EASL Liver Cancer Summit 2023, in light of the recent EASL policy statement for patients with cirrhosis.

You May Also Like

2 October 2023

Patient-centric and ecosystem insights into hepatocellular carcinoma across Asia-Pacific – LEAP

In this white paper, insights on the liver ecosystem are uncovered, with the intention of facilitating action among various stakeholders to reduce liver cancer incidence and mortality in APAC. Read…

Read More
23 August 2023

Building modern hepatocellular carcinoma surveillance programmes: taking steps to address a leading cause of liver cancer death in Asia

In this whitepaper, HCC surveillance programs in Asia were analysed. The learnings from well established HCC surveillance programs, as well as the challenges in areas that have not implemented such…

Read More
18 August 2023

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia

This study aimed to evaluate the economic impact of upfront NGS compared to testing modalities in East Asian patients with mNSCLC, by using Hong Kong as an example.

Read More


Be the first to receive updates, event opportunities, and thought leadership insights.